Julia L Glade Bender

List of Publications by Year
in descending order

81 papers	3,605 citations	147566 31 h-index	138251 58 g-index
83 all docs	83 docs citations	83 times ranked	5319 citing authors

#	Article	IF	Citations
1	Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2008, 26, 399-405.	0.8	240
2	Irinotecanâ€“temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2017, 18, 946-957.	5.1	205
3	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1â€“2 trial. Lancet Oncology, The, 2020, 21, 121-133.	5.1	204
4	Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors. JAMA Oncology, 2016, 2, 608.	3.4	172
5	VEGF blocking therapy in the treatment of cancer. Expert Opinion on Biological Therapy, 2003, 3, 263-276.	1.4	159
6	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine, 2016, 8, 133.	3.6	147
7	CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to Î³-secretase inhibitors. Leukemia, 2006, 20, 1279-1287.	3.3	141
8	Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Journal of Clinical Oncology, 2013, 31, 3034-3043.	0.8	138
9	Recurrent EML4â€“NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. Modern Pathology, 2018, 31, 463-473.	2.9	117
10	Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia (TACL) consortium. Pediatric Blood and Cancer, 2010, 55, 254-259.	0.8	104
11	Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study. Clinical Cancer Research, 2011, 17, 5113-5122.	3.2	104
12	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2012, 18, 6011-6022.	3.2	103
13	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2020, 38, 2160-2169.	0.8	98
14	Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. Journal of Pediatrics, 2001, 138, 862-867.	0.9	84
15	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resistance Updates, 2004, 7, 289-300.	6.5	82
16	Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorhamâ€“Stout disease. Pediatric Blood and Cancer, 2019, 66, e27614.	0.8	81
17	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	5.7	74
18	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	5.8	63

#	Article	IF	Citations
19	Angiogenesis and vascular targeting in Ewing sarcoma. Cancer, 2010, 116, 749-757.	2.0	58
20	Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Childrenâ€™s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force. F1000Research, 2019, 8, 493.	0.8	57
21	Nutritional status and clinical outcomes in pediatric patients with solid tumors : A systematic review of the literature. Seminars in Oncology, 2019, 46, 48-56.	0.8	52
22	Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience. Pediatric Blood and Cancer, 2016, 63, 1974-1982.	0.8	49
23	Immunotherapeutic Targeting of GPC3 in Pediatric Solid Embryonal Tumors. Frontiers in Oncology, 2019, 9, 108.	1.3	49
24	Neuropsychological functioning of children treated with intensive chemotherapy followed by myeloablative consolidation chemotherapy and autologous hematopoietic cell rescue for newly diagnosed CNS tumors: An analysis of the Head Start II survivors. Pediatric Blood and Cancer, 2010, 54, 429-436.	0.8	47
25	COVIDâ€19 disease in New York City pediatric hematology and oncology patients. Pediatric Blood and Cancer, 2020, 67, e28420.	0.8	44
26	Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Journal of Physical Education and Sports Management, 2015, 1, a000471.	0.5	39
27	Pediatric oncology enters an era of precision medicine. Current Problems in Cancer, 2017, 41, 194-200.	1.0	39
28	Characterization of on-target adverse events caused by TRK inhibitor therapy. Annals of Oncology, 2020, 31, 1207-1215.	0.6	39
29	Current Issues in Wilms Tumor Management. Current Problems in Cancer, 2005, 29, 223-260.	1.0	38
30	Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer. Supportive Care in Cancer, 2017, 25, 701-708.	1.0	37
31	Inhibition of Cyclooxygenase-2 Disrupts Tumor Vascular Mural Cell Recruitment and Survival Signaling. Cancer Research, 2006, 66, 4378-4384.	0.4	34
32	Unrealistic parental expectations for cure in poorâ€prognosis childhood cancer. Cancer, 2020, 126, 416-424.	2.0	34
33	Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Childrenâ€™s Oncology Group study. Cancer Chemotherapy and Pharmacology, 2012, 69, 1021-1027.	1.1	31
34	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. Pediatric Blood and Cancer, 2018, 65, e27023.	0.8	31
35	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers. Nature Communications, 2022, 13, 2485.	5.8	31
36	Translating genomic discoveries to the clinic in pediatric oncology. Current Opinion in Pediatrics, 2015, 27, 34-43.	1.0	29

#	Article	IF	Citations
37	Clinical trial enrollment of adolescents and young adults with sarcoma. Cancer, 2017, 123, 3434-3440.	2.0	29
38	Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. Frontiers in Pediatrics, 2017, 5, 265.	0.9	29
39	Activity of the Highly Specific RET Inhibitor Selpercatinib (LOXO-292) in Pediatric Patients With Tumors Harboring RET Gene Alterations. JCO Precision Oncology, 2020, 4, 341-347.	1.5	29
40	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clinical Cancer Research, 2020, 26, 2297-2307.	3.2	28
41	Growth plate abnormalities in pediatric cancer patients undergoing phase 1 antiâ€angiogenic therapy: A report from the children's oncology group phase I consortium. Pediatric Blood and Cancer, 2015, 62, 45-51.	0.8	27
42	Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research. Pediatric Blood and Cancer, 2015, 62, 1374-1380.	0.8	27
43	Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs, 2017, 5, 355-368.	0.5	27
44	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. Journal of Pain and Symptom Management, 2020, 60, 782-789.	0.6	27
45	Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatric Blood and Cancer, 2009, 52, 669-671.	0.8	25
46	A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Journal of Physical Education and Sports Management, 2017, 3, a001396.	0.5	25
47	Opportunities and Challenges in Drug Development for Pediatric Cancers. Cancer Discovery, 2021, 11, 545-559.	7.7	25
48	Clinical Development of VEGF Signaling Pathway Inhibitors in Childhood Solid Tumors. Oncologist, 2011, 16, 1614-1625.	1.9	23
49	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clinical Cancer Research, 2012, 18, 5081-5089.	3.2	22
50	Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. European Journal of Cancer, 2018, 100, 27-34.	1.3	22
51	Pediatric allo-SCT for malignant and non-malignant diseases: impact on health-related quality of life outcomes. Bone Marrow Transplantation, 2013, 48, 787-793.	1.3	20
52	Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nature Medicine, 2022, 28, 1581-1589.	15.2	16
53	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Medicine, 2016, 8, 116.	3.6	15
54	Psychosocial Needs and Preferences for Care among Adolescent and Young Adult Cancer Patients (Ages 15â€“39): A Qualitative Study. Cancers, 2022, 14, 710.	1.7	14

#	Article	IF	Citations
55	A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatric Hematology and Oncology, 2020, 37, 465-474.	0.3	12
56	Treatment of Metastatic, Refractory Alveolar Soft Part Sarcoma: Case Reports and Literature Review of Treatment Options in the Era of Targeted Therapy. Journal of Pediatric Hematology/Oncology, 2016, 38, e169-e172.	0.3	11
57	Duality of Purpose: Participant and Parent Understanding of the Purpose of Genomic Tumor Profiling Research Among Children and Young Adults With Solid Tumors. JCO Precision Oncology, 2019, 3, 1-17.	1.5	11
58	Bromodomain and extra-terminalÂinhibitorsâ€"A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in childrenâ€"ACCELERATE. European Journal of Cancer, 2021, 146, 115-124.	1.3	10
59	Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Research Notes, 2014, 7, 256.	0.6	9
60	Epigenetic Combination Therapy for Children With Secondary Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) and Concurrent Solid Tumor Relapse. Journal of Pediatric Hematology/Oncology, 2017, 39, 560-564.	0.3	8
61	Germline Sequencing Improves Tumor-Only Sequencing Interpretation in a Precision Genomic Study of Patients With Pediatric Solid Tumor. JCO Precision Oncology, 2021, 5, 1840-1852.	1.5	8
62	Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations. JCO Precision Oncology, 2018, 2, 1-11.	1.5	5
63	Integrated analysis of longâ€term growth and bone development in pediatric and adolescent patients receiving bevacizumab. Pediatric Blood and Cancer, 2019, 66, e27487.	0.8	5
64	A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. Journal of Neuro-Oncology, 2020, 149, 437-445.	1.4	5
65	Phase I study of sorafenib in children with refractory solid tumors: A Children's Oncology Group Phase I Consortium trial. Journal of Clinical Oncology, 2009, 27, 10012-10012.	0.8	5
66	Basic Principles of Gene Transfer in Hematopoietic Stem Cells. , 1999, 36, 1-19.		4
67	Patterns of Translocation Testing in Patients Enrolling in a Cooperative Group Trial for Newly Diagnosed Metastatic Ewing Sarcoma. Archives of Pathology and Laboratory Medicine, 2021, 145, 1564-1568.	1.2	4
68	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of Clinical Oncology, 2021, 39, 3822-3828.	0.8	4
69	Remarkable Activity of Bortezomib Combined with Chemotherapy in a Phase I Study of Relapsed Childhood Acute Lymphoblastic Leukemia (ALL). A Report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium.. Blood, 2008, 112, 1919-1919.	0.6	4
70	Abstract 1122: Germline mutation prevalence in young adults with cancer. , 2020, , .		3
71	CIC-Mediated Modulation of MAPK Signaling Opposes Receptor Tyrosine Kinase Inhibitor Response in Kinase-Addicted Sarcoma. Cancer Research, 2022, 82, 1110-1127.	0.4	3
72	INI1 negative hepatoblastoma, a vanishing entity representing malignant rhabdoid tumor. Human Pathology: Case Reports, 2018, 12, 42-47.	0.2	2

#	Article	IF	Citations
73	Identification of a secondary RET mutation in a pediatric patient with relapsed acute myeloid leukemia leads to the diagnosis and treatment of asymptomatic metastatic medullary thyroid cancer in a parent: a case for sequencing the germline. Journal of Physical Education and Sports Management, 2019, 5, a003889.	0.5	2
74	Stepwise Strategic Mitigation Planning in a Pediatric Oncology Center During the COVID-19 Pandemic. Journal of Pediatric Oncology Nursing, 2021, 38, 176-184.	1.5	2
75	Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia. Blood, 2016, 128, 5250-5250.	0.6	1
76	VEGF blocking therapy in the treatment of cancer. , 0, .		1
77	COVID-19 in New York City Pediatric Hematology and Oncology Patients. SSRN Electronic Journal, 0, , .	0.4	1
78	Drug Induced Non-Specific Interstitial Pneumonitis. , 2011, , .		0
79	Clinical Implementation of Genomic Sequencing in Pediatric Oncology: Identification and Valuation of Resources and Costs Associated with Next-Generation Sequencing. Value in Health, 2014, 17, A645.	0.1	0
80	Knowledge, attitudes, and beliefs of parents toward whole-genome sequencing in pediatric cancer.. Journal of Clinical Oncology, 2014, 32, 10090-10090.	0.8	0
81	Abstract 3104: A high prevalence of chromosomal translocations as drivers in high-risk pediatric solid cancers. , 2019, , .		0